Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
Is there a role of everolimus or capecitabine and temozolomide in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia in patients already on octreotide?
The key question is why there is a reason to change the treatment... Is it for worsening symptoms or progressive disease with overt lung NET development or progression of known lung NET?In a retrospective study of 55 patients with DIPNECH, only 18% had a progression to a lung NET (typical carcinoid)...
How do you utilize p53 NGS testing in your treatment planning for patients with CLL?
When I approach consideration of treatment, it is clear that TP53 mutation or del(17)(p13) chromosome region on interphase cytogenetics identifies a group of patients at risk for progression after treatment with a venetoclax containing regimen and also to a lesser extent BTKi (ibrutinib/acalabrutini...
What is your treatment approach for a recurrent brainstem glioma?
Recurrent brainstem glioma is a very challenging situation. One could consider participating in a clinical trial if available, especially one that targets some of the known mutations in the tumor (such as histone h3, TP53, ATRX, ACVR1, and others). We have previously re-irradiated a few patients at ...
Do you routinely obtain next generation sequencing for patients with metastatic renal cell carcinoma and if so, what is your approach to incorporating these results into treatment decision making?
Currently, I do not routinely send NGS for patients with metastatic clear cell RCC as we do not have level 1 evidence that these results should guide treatment decisions. We do not have "actionable mutations" that would change or guide our treatment of choice. IMDC still remains our best risk strati...
What clinical and pathological features do you consider when deciding which androgen receptor targeted agent to combine with ADT for a patient with newly diagnosed castrate sensitive metastatic prostate cancer?
Regarding which novel hormonal agent I use with ADT, there are no specific pathologic features which suggest that any one agent is better than any others as far as I know, so I do not consider that in the decision. The primary reasons why I choose an agent are based on adverse events and side effect...
What is your approach to first line systemic treatment for low risk gestational trophoblastic neoplasia?
Patients with gestational trophoblastic disease and a WHO score < 6 are classified as low risk. In patients who desire retention of fertility, the first line treatment is chemotherapy which achieves typically very high remission rates/cure rates. The most frequently used first line regimens employ m...
How do you manage triple negative primary squamous cell carcinoma of the breast?
Rare disease with no defined SOC but limited literature suggest poor outcomes as they don’t respond to systemic treatment like TNBC.Hennessy et al., PMID 16258085
Is oral lichen planus a contraindication for immunotherapy in a patient with recurrent oral SCC?
I have personally given Pembrolizumab to a patient with an oral SCC who had underlying lichen planus. The patient had a good response to therapy, but I also treated the patient with a conditioning regimen of steroids during treatment so as not to exacerbate the lichen planus. I gave prednisone 40 mg...
How would you manage an adult patient status post subtotal resection of spinal osteoblastoma?
US can be helpful if performed serially. If/when there is evidence of growth, discuss ablation options with IR if feasible.
What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?
To some extent, it really will depend on how aggressively the disease is behaving. Most PCL cases are quite aggressive and need urgent therapy. For an extremely fit individual who is usually in the inpatient setting, I opt for VD-PACE (usually the IMiD is not available quickly). I will perform a TTE...